Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


New therapeutic approaches for non-muscle invasive bladder cancer (NMIBC): intravesical use of OncoTherad biological response modifier and its association with platelet rich plasma (PRP)

Funder: São Paulo Research Foundation

Funding period
Funding amount
Bladder cancer (BC) is the second most common malignant disease of the urinary tract, and one of the most costly neoplasms for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to decrease recurrence and prevent tumor progression. However, the use of BCG is associated with side effects of varying intensities, ranging from mild irritative symptoms to severe systemic reaction, which contributes to treatment discontinuation and has a post-treatment recurrence rate of up to 30%. In this way, the development of new therapies for the treatment of CBNMI, which are more effective and present less adverse effects than the classic therapies, are very relevant. Considering the importance of the development of drugs that can be administered intravesically and acting as modulators of the immune system, our research group developed a synthetic nanostructured compound with antitumor and immunological properties called OncoTherad (MRB-CFI-1 - Biological Response Modifier - Inorganic Phosphate Complex 1). Our group demonstrated that in the treatment of chemically induced CBNMI in mice, OncoTherad led to significant tumor regression, indicating a significant antitumor effect of this compound involving the interferon signaling pathway for Toll-like receptors (TLRs) 2 and 4-mediated. In addition, the use of phosphate moieties can exert a number of biological activities, since polyphosphates (PolyP) are secreted by activated platelets and mast cells, interfering in coagulation and innate immune response. Considering the importance of the modulation of the receptors of the immune system by these phosphate species and their relation with activated platelets, our research group investigated the importance of Platelet Rich Plasma (PRP) in the modulation of these receptors and demonstrated that PRP was able to exert antitumor effects mediated by the immune system. Thus, the main objectives of this study will be to characterize the histopathological and molecular effects of the OncoTherad nanostructured complex associated with PRP in the treatment of CBNMI chemically induced in mice, as well as to establish the possible mechanisms of action of this therapeutic association involving the TLRs 2 and 4 signaling pathways, STAT/ JAK1/JAK2 and RANK/ RANKL/ OPG cell signaling pathways, PDGF/ IGF-1/ TGF-² growth factors, and PD-1/ PD-L1 immune checkpoint pathway. (AU)
Similar projects All >
Sorted by: Start Date
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
[Efficacy and toxicity of bladder instillation of anti-tumor peptide for inhibition of bladder tumor in mice] - Original in Japanese

Japan Society for the Promotion of Science to Toru SHIMAZUI, Hiroyuki NISHIYAMA, Takahiro Kojima, Kazuhiro YOSHIKAWA

USD 39,492
2019 - 2022
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 372,404
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 1,313,632
2019 - 2024



    1107 Immunology


    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC

    Urologic Diseases




    5.1 Pharmaceuticals

  • Health Research Areas


  • Broad Research Areas

    Basic Science